Market Spotlight: Glioblastoma
Market Spotlight: Glioblastoma
$1,318.00
This Market Spotlight report covers the Glioblastoma market, comprising key marketed and pipeline drugs, clinical trials, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Glioblastoma market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2019, there were 77,000 incident cases of glioblastoma worldwide, and forecasts that number to increase to 91,800 incident cases by 2028.
- It is estimated that the majority of diagnosed cases were in males in 2019. Approved drugs in the glioblastoma space focus on DNA, vascular endothelial growth factor, DNA synthesis, protein synthesis, and RNA synthesis. These drugs are administered via the intravenous, intratumoral, and oral routes for glioblastoma.
- The majority of industry-sponsored drugs in active clinical development for glioblastoma are in Phase II, with three drugs in the NDA/BLA phase.
- Therapies in mid- and late-stage development for glioblastoma focus on a wide variety of targets. The majority of pipeline drugs for glioblastoma are administered via the oral and intravenous routes.
- High-impact upcoming events for drugs in the glioblastoma space comprise topline Phase I/II trial results for Calquence and NOX-A12, topline Phase II trial results for ABI-009, topline Phase II/III trial results for omburtamab, Phase III updated trial results for DCVax-Brain and Trans Sodium Crocetinate (TSC), and expected PDUFA dates for biosimilar bevacizumab (Mylan/Biocon) and Danyelza.
- The overall likelihood of approval of a Phase I solid tumors asset is 5.8%, and the average probability a drug advances from Phase III is 43.3%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.4 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for glioblastoma have been in the early and mid-phases of development, with 92% of trials in Phase I–II, and only 8% in Phase III–IV.
- The US has a substantial lead in the number of glioblastoma clinical trials globally. France leads the major European markets, while China has the top spot in Asia.
- Clinical trial activity in the glioblastoma space is dominated by completed trials. Merck & Co has the highest number of completed clinical trials for glioblastoma, with 79 trials.
- Merck & Co leads industry sponsors with the highest overall number of clinical trials for glioblastoma, followed by Roche
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Disease definition
8 Patient segmentation
8 Symptoms
8 Risk factors
9 Diagnosis
10 TREATMENT
10 Surgery
10 Radiation therapy
10 Chemotherapy
10 Tumor-treating fields (TTFs)
11 Targeted therapy
12 EPIDEMIOLOGY
16 MARKETED DRUGS
19 PIPELINE DRUGS
36 RECENT EVENTS AND ANALYST OPINION
36 AG-881 for Glioblastoma (May 29, 2020)
36 FT-2102 for Glioblastoma (May 28, 2020)
38 Toca 511 for Glioblastoma (September 12, 2019)
40 Opdivo for Glioblastoma (September 5, 2019)
41 Mvasi for Glioblastoma (June 25, 2019)
42 GammaTile for Glioblastoma (June 17, 2019)
44 Qinlock for Glioblastoma (June 11, 2019)
45 AG-881 for Glioblastoma (June 3, 2019)
46 Multiple Drugs for Glioblastoma (June 3, 2019)
47 Opdivo for Glioblastoma (May 9, 2019)
49 Optune for Glioblastoma (April 23, 2019)
50 Optune for Glioblastoma (February 28, 2019)
52 KEY UPCOMING EVENTS
53 KEY REGULATORY EVENTS
53 New Approvals In Spotlight As China Gears For National Congress
53 Mylan Reveals FDA Goal Date For Bevacizumab
53 Pfizer Could Launch US Bevacizumab This Year Despite Patent Thicket
54 PROBABILITY OF SUCCESS
55 LICENSING AND ASSET ACQUISITION DEALS
55 HLB Takes First Expansion Step Via Immunomic Acquisition
55 Fosun Gains Chinese Rights To MimiVax’s SurVaxM
55 Deals Shaping The Medical Industry, October 2019
57 REVENUE OPPORTUNITY
58 CLINICAL TRIAL LANDSCAPE
59 Sponsors by status
60 Sponsors by phase
62 BIBLIOGRAPHY
63 Prescription information
64 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in incident cases of glioblastoma, 2019–28
19 Figure 2: Overview of pipeline drugs for glioblastoma in the US
19 Figure 3: Pipeline drugs for glioblastoma, by company
20 Figure 4: Pipeline drugs for glioblastoma, by drug type
20 Figure 5: Pipeline drugs for glioblastoma, by classification
38 Figure 6: FT-2102 for Glioblastoma (May 28, 2020): Phase I/II – 2101-ONC-102
40 Figure 7: Toca 511 for Glioblastoma (September 12, 2019): Phase III – Toca 5 (w/Lomustine)
41 Figure 8: Opdivo for Glioblastoma (September 5, 2019): Phase III – CheckMate-548
49 Figure 9: Opdivo for Glioblastoma (May 9, 2019): Phase III – CheckMate 498 (vs. Temozolomide)
52 Figure 10: Key upcoming events in glioblastoma
54 Figure 11: Probability of success in the glioblastoma pipeline
58 Figure 12: Clinical trials in glioblastoma
58 Figure 13: Top 10 drugs for clinical trials in glioblastoma
59 Figure 14: Top 10 companies for clinical trials in glioblastoma
59 Figure 15: Trial locations in glioblastoma
60 Figure 16: Glioblastoma trials status
61 Figure 17: Glioblastoma trials sponsors, by phase
LIST OF TABLES
13 Table 1: Global incident cases of glioblastoma, 2019–28
15 Table 2: Incident cases of glioblastoma, by gender, 2019
17 Table 3: Marketed drugs for glioblastoma
21 Table 4: Pipeline drugs for glioblastoma in the US
36 Table 5: AG-881 for Glioblastoma (May 29, 2020)
37 Table 6: FT-2102 for Glioblastoma (May 28, 2020)
39 Table 7: Toca 511 for Glioblastoma (September 12, 2019)
40 Table 8: Opdivo for Glioblastoma (September 5, 2019)
42 Table 9: Mvasi for Glioblastoma (June 25, 2019)
43 Table 10: GammaTile for Glioblastoma (June 17, 2019)
45 Table 11: Ripretinib for Glioblastoma (June 11, 2019)
46 Table 12: AG-881 for Glioblastoma (June 3, 2019)
47 Table 13: Multiple Drugs for Glioblastoma (June 3, 2019)
48 Table 14: Opdivo for Glioblastoma (May 9, 2019)
49 Table 15: Optune for Glioblastoma (April 23, 2019)
51 Table 16: Optune for Glioblastoma (February 28, 2019)
57 Table 17: Historical global sales, by drug ($m), 2015–19
57 Table 18: Forecasted global sales, by drug ($m), 2020-24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Idiopathic pulmonary fibrosis (IPF) 
Sign up to the